Improvement in parameters of hematologic and immunologic function and patient well-being in the phase III RESONATE study of Ibrutinib versus ofatumumab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Barrientos, J; O'Brien, S; Brown, J; Kay, N; Reddy, N; Coutre, S; Tam, C; Mulligan, S; Jaeger, U; Devereux, S; Pocock, C; Robak, T; Schuster, S; Schuh, A; Gill, D; Bloor, Adrian; Dearden, C; Moreno, C; Cull, G; Hamblin, M; Jones, J; Eckert, K; Solman, I; Suzuki, S; Hsu, E; James, D; Byrd, J; Hillmen, P

Name:

PIIS2152265018305743.pdf

Size:

2.405Mb

Format:

PDF

Description:

Full text, Open Access article

Download

Affiliation

Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY

Issue Date

2018-08-18

Metadata

Show full item record

Abstract

Ibrutinib compared with ofatumumab significantly improves progression-free and overall survival in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Citation

Improvement in parameters of hematologic and immunologic function and patient well-being in the phase III RESONATE study of Ibrutinib versus ofatumumab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. 2018, Clin Lymphoma Myeloma Leuk

Journal

Clinical Lymphoma, Myeloma & Leukemia

URI

http://hdl.handle.net/10541/621302

DOI

10.1016/j.clml.2018.08.007

PubMed ID

30249389

Type

Article

Language

ISSN

2152-2669

Collections

All Christie Publications